Full Transcript Introduction to Retatrutide 0:01 Lisa Broyles here with Way Too Health 0:01 Lisa Broyles here with Way Too Health MD, and this is a two-video series, mini 0:05 MD, and this is a two-video series, mini 0:05 MD, and this is a two-video series, mini series I guess, about the newest GLP-1 0:08 series I guess, about the newest GLP-1 0:08 series I guess, about the newest GLP-1 agonist. So, we've all heard of Ozempic, 0:10 agonist. So, we've all heard of Ozempic, 0:10 agonist. So, we've all heard of Ozempic, we've all heard of Mounjaro, which is 0:12 we've all heard of Mounjaro, which is 0:12 we've all heard of Mounjaro, which is tirzepatide, but there is a new third 0:16 tirzepatide, but there is a new third 0:16 tirzepatide, but there is a new third drug in the pipeline by Eli Lilly, and 0:19 drug in the pipeline by Eli Lilly, and 0:19 drug in the pipeline by Eli Lilly, and it is called retatrutide. 0:22 it is called retatrutide.
What the Drug Is and Trial Status 0:23 it is called retatrutide. In this video about what the research 0:24 In this video about what the research 0:24 In this video about what the research says, what the studies are saying, what 0:26 says, what the studies are saying, what 0:26 says, what the studies are saying, what this drug can actually do. And in the 0:28 this drug can actually do. And in the 0:28 this drug can actually do. And in the second video, we're we'll talk about the 0:30 second video, we're we'll talk about the 0:30 second video, we're we'll talk about the dangers of it and what you can do to try 0:32 dangers of it and what you can do to try 0:32 dangers of it and what you can do to try to mitigate that if you find that you 0:34 to mitigate that if you find that you 0:34 to mitigate that if you find that you need to be on this 0:36 need to be on this 0:36 need to be on this medication. So, first of all, I want to 0:38 medication. So, first of all, I want to 0:38 medication. So, first of all, I want to say that retatrutide 0:40 say that retatrutide 0:40 say that retatrutide has It's hard to say that word. Has not 0:43 has It's hard to say that word. Has not 0:43 has It's hard to say that word. Has not been FDA-approved. It is in phase three 0:46 been FDA-approved. It is in phase three 0:46 been FDA-approved. It is in phase three clinical trials. This means it's in 0:48 clinical trials. This means it's in 0:48 clinical trials. This means it's in human studies right now, okay? So, this 0:51 human studies right now, okay? So, this 0:51 human studies right now, okay? So, this drug is not available yet except as a 0:54 drug is not available yet except as a 0:54 drug is not available yet except as a research-only 0:56 research-only 0:56 research-only peptide. So, some compounding pharmacies
Clinical Trials and Study Groups 0:59 peptide. So, some compounding pharmacies 0:59 peptide. So, some compounding pharmacies are making it and selling it, but it is 1:02 are making it and selling it, but it is 1:02 are making it and selling it, but it is not yet FDA-approved because the studies 1:04 not yet FDA-approved because the studies 1:04 not yet FDA-approved because the studies aren't complete. So, basically, what we 1:07 aren't complete. So, basically, what we 1:07 aren't complete. So, basically, what we know right now is that there are these 1:10 know right now is that there are these 1:10 know right now is that there are these triumph trials that are being done by 1:13 triumph trials that are being done by 1:13 triumph trials that are being done by Eli Lilly across 14 countries, 5,800 1:17 Eli Lilly across 14 countries, 5,800 1:17 Eli Lilly across 14 countries, 5,800 people in these studies. Okay? So, what 1:19 people in these studies. Okay? So, what 1:19 people in these studies. Okay? So, what they are doing is they are doing a 4-mg, 1:22 they are doing is they are doing a 4-mg, 1:22 they are doing is they are doing a 4-mg, a 9-mg, and a 12-mg dose of retatrutide 1:26 a 9-mg, and a 12-mg dose of retatrutide 1:26 a 9-mg, and a 12-mg dose of retatrutide in escalating doses to get to that 9- to
Weight Loss and Health Benefits 1:28 in escalating doses to get to that 9- to 1:28 in escalating doses to get to that 9- to 12-mg dose, and they're looking at 1:31 12-mg dose, and they're looking at 1:31 12-mg dose, and they're looking at patients that are obese and also have 1:35 patients that are obese and also have 1:35 patients that are obese and also have either obstructive sleep apnea, 1:37 either obstructive sleep apnea, 1:37 either obstructive sleep apnea, osteoarthritis of the knees, or 1:39 osteoarthritis of the knees, or 1:39 osteoarthritis of the knees, or cardiovascular disease. So, there's 1:41 cardiovascular disease. So, there's 1:41 cardiovascular disease. So, there's multiple studies going on looking at 1:43 multiple studies going on looking at 1:43 multiple studies going on looking at different endpoints and what the weight 1:45 different endpoints and what the weight 1:45 different endpoints and what the weight loss of the drug does to these different 1:47 loss of the drug does to these different 1:47 loss of the drug does to these different endpoints, okay? I will start by saying 1:49 endpoints, okay? I will start by saying 1:50 endpoints, okay? I will start by saying what these studies have found, and this 1:51 what these studies have found, and this 1:51 what these studies have found, and this is exploding across the medical 1:54 is exploding across the medical 1:54 is exploding across the medical community, and you're probably hearing 1:56 community, and you're probably hearing 1:56 community, and you're probably hearing about it because the doses of 9 to 12 mg 2:00 about it because the doses of 9 to 12 mg 2:00 about it because the doses of 9 to 12 mg are causing anywhere from 24 to 27% 2:05 are causing anywhere from 24 to 27% 2:05 are causing anywhere from 24 to 27% weight loss over 48 weeks. This is a 2:08 weight loss over 48 weeks. This is a 2:08 weight loss over 48 weeks. This is a massive amount of weight loss. So, 2:11 massive amount of weight loss. So, 2:11 massive amount of weight loss. So, they're finding that people that reached 2:13 they're finding that people that reached 2:13 they're finding that people that reached a plateau on Ozempic or Mounjaro on this 2:17 a plateau on Ozempic or Mounjaro on this 2:17 a plateau on Ozempic or Mounjaro on this drug are easily breaking through that 2:19 drug are easily breaking through that 2:19 drug are easily breaking through that with faster weight loss and not just 2:21 with faster weight loss and not just 2:21 with faster weight loss and not just weight loss, but they are losing their 2:23 weight loss, but they are losing their 2:23 weight loss, but they are losing their intra-organ fat. Okay, the fat in the 2:26 intra-organ fat. Okay, the fat in the 2:26 intra-organ fat. Okay, the fat in the liver. So, we are now estimating that
How Retatrutide Works 2:28 liver. So, we are now estimating that 2:28 liver. So, we are now estimating that one in three 2:30 one in three 2:30 one in three people in the United States have some 2:33 people in the United States have some 2:33 people in the United States have some level of fat infiltrating the liver. 2:35 level of fat infiltrating the liver. 2:36 level of fat infiltrating the liver. This is from what we call metabolic 2:37 This is from what we call metabolic 2:37 This is from what we call metabolic syndrome. It's from us Americans having 2:40 syndrome. It's from us Americans having 2:40 syndrome. It's from us Americans having too much food, not enough exercise. 2:42 too much food, not enough exercise. 2:42 too much food, not enough exercise. Okay, the fat accumulates in the liver, 2:45 Okay, the fat accumulates in the liver, 2:45 Okay, the fat accumulates in the liver, eventually causes scarring and permanent 2:47 eventually causes scarring and permanent 2:47 eventually causes scarring and permanent liver damage. So, this is called 2:49 liver damage. So, this is called 2:49 liver damage. So, this is called non-alcoholic 2:51 non-alcoholic 2:51 non-alcoholic steatosis, 2:52 steatosis, 2:52 steatosis, NASH syndrome, metabolic fatty liver, 2:55 NASH syndrome, metabolic fatty liver, 2:55 NASH syndrome, metabolic fatty liver, non-alcoholic. If you have fat in the 2:58 non-alcoholic. If you have fat in the 2:58 non-alcoholic. If you have fat in the liver, this is a drug that can literally 3:01 liver, this is a drug that can literally 3:01 liver, this is a drug that can literally melt that fat. It makes It increases 3:05 melt that fat. It makes It increases 3:05 melt that fat. It makes It increases something called thermogenesis. Okay, 3:08 something called thermogenesis. Okay, 3:08 something called thermogenesis. Okay, that 14% of the people on the 9 mg dose 3:12 that 14% of the people on the 9 mg dose 3:12 that 14% of the people on the 9 mg dose of retatrutide completely resolved their 3:15 of retatrutide completely resolved their 3:15 of retatrutide completely resolved their knee pain. Gone because of their weight 3:18 knee pain. Gone because of their weight 3:18 knee pain. Gone because of their weight loss. Those knees aren't carrying around 3:19 loss. Those knees aren't carrying around 3:19 loss. Those knees aren't carrying around so much weight, they don't hurt as much. 3:22 so much weight, they don't hurt as much. 3:22 so much weight, they don't hurt as much. They saw a decrease in apneic events in 3:25 They saw a decrease in apneic events in 3:25 They saw a decrease in apneic events in obstructive sleep apnea. They saw a 3:27 obstructive sleep apnea. They saw a 3:27 obstructive sleep apnea. They saw a reduction in cholesterol levels, hs-CRP, 3:31 reduction in cholesterol levels, hs-CRP, 3:31 reduction in cholesterol levels, hs-CRP, which is inflammation in the heart 3:32 which is inflammation in the heart 3:33 which is inflammation in the heart arteries, decrease in blood pressure by 3:35 arteries, decrease in blood pressure by 3:35 arteries, decrease in blood pressure by as much as 14 points systolic on the 12
Fat Burning, Side Effects, and Muscle Loss 3:38 as much as 14 points systolic on the 12 3:38 as much as 14 points systolic on the 12 mg dose. So, you're seeing major 3:41 mg dose. So, you're seeing major 3:41 mg dose. So, you're seeing major improvements in people's health after 48 3:44 improvements in people's health after 48 3:44 improvements in people's health after 48 weeks on this drug. So, how does it 3:46 weeks on this drug. So, how does it 3:46 weeks on this drug. So, how does it work? So, Ozempic balances the GLP 3:50 work? So, Ozempic balances the GLP 3:50 work? So, Ozempic balances the GLP receptor. I've covered this in other 3:52 receptor. I've covered this in other 3:52 receptor. I've covered this in other videos. Not there's appetite covers the 3:54 videos. Not there's appetite covers the 3:55 videos. Not there's appetite covers the GLP and the GIP, which blocks the nausea 3:58 GLP and the GIP, which blocks the nausea 3:58 GLP and the GIP, which blocks the nausea that commonly occurs with the first drug 4:01 that commonly occurs with the first drug 4:01 that commonly occurs with the first drug Ozempic, okay? So, that's why 4:03 Ozempic, okay? So, that's why 4:03 Ozempic, okay? So, that's why tirzepatide is more easily tolerated 4:06 tirzepatide is more easily tolerated 4:06 tirzepatide is more easily tolerated than Ozempic or semaglutide. However, 4:09 than Ozempic or semaglutide. However, 4:09 than Ozempic or semaglutide. However, this third drug also stimulates the 4:12 this third drug also stimulates the 4:12 this third drug also stimulates the glucagon receptor. Now, typically 4:15 glucagon receptor. Now, typically 4:15 glucagon receptor. Now, typically glucagon has been seen as the villain in 4:17 glucagon has been seen as the villain in 4:17 glucagon has been seen as the villain in weight loss treatments because tells the 4:19 weight loss treatments because tells the 4:19 weight loss treatments because tells the liver release blood sugar. So, typically 4:22 liver release blood sugar. So, typically 4:22 liver release blood sugar. So, typically we don't want glucagon because it's the 4:23 we don't want glucagon because it's the 4:23 we don't want glucagon because it's the opposite of insulin. However, scientists 4:26 opposite of insulin. However, scientists 4:26 opposite of insulin. However, scientists discovered that when you stimulate GLP, 4:29 discovered that when you stimulate GLP, 4:29 discovered that when you stimulate GLP, GIP, and glucagon receptors all at the 4:32 GIP, and glucagon receptors all at the 4:32 GIP, and glucagon receptors all at the same time, you get thermogenesis. This 4:35 same time, you get thermogenesis. This 4:35 same time, you get thermogenesis. This is literally what it sounds like. It 4:37 is literally what it sounds like. It 4:37 is literally what it sounds like. It revs up the heat, okay? And it literally 4:42 revs up the heat, okay? And it literally 4:42 revs up the heat, okay? And it literally melts intra-abdominal fat in glucagon 4:45 melts intra-abdominal fat in glucagon 4:45 melts intra-abdominal fat in glucagon receptor at the same time as the other 4:48 receptor at the same time as the other 4:48 receptor at the same time as the other receptors. And it does this by enhancing 4:50 receptors. And it does this by enhancing 4:50 receptors. And it does this by enhancing the mitochondria, which we've talked 4:52 the mitochondria, which we've talked 4:52 the mitochondria, which we've talked about before. Those are your energy 4:53 about before. Those are your energy 4:53 about before. Those are your energy cells. It turns up turns on the gas. It 4:57 cells. It turns up turns on the gas. It 4:57 cells. It turns up turns on the gas. It makes those mitochondria work extra hard 5:00 makes those mitochondria work extra hard 5:00 makes those mitochondria work extra hard to produce energy to melt fat, okay? The 5:04 to produce energy to melt fat, okay? The 5:04 to produce energy to melt fat, okay? The one problem here is that it melts fat, 5:07 one problem here is that it melts fat, 5:07 one problem here is that it melts fat, but you're also melting muscle. So, 5:09 but you're also melting muscle. So, 5:09 but you're also melting muscle. So, that's what we're going to talk about in 5:10 that's what we're going to talk about in 5:10 that's what we're going to talk about in video two is how can we prevent muscle 5:12 video two is how can we prevent muscle 5:12 video two is how can we prevent muscle loss? So, it works by stimulating those 5:14 loss? So, it works by stimulating those 5:15 loss? So, it works by stimulating those three receptors. You're burning fat at 5:17 three receptors. You're burning fat at 5:17 three receptors. You're burning fat at an incredible rate. Your body is 5:19 an incredible rate. Your body is 5:19 an incredible rate. Your body is literally sitting still, but go burning 5:21 literally sitting still, but go burning 5:22 literally sitting still, but go burning the energy of running a half marathon on 5:24 the energy of running a half marathon on 5:24 the energy of running a half marathon on this drug. Increased heart rate, 5:26 this drug. Increased heart rate, 5:26 this drug. Increased heart rate, possibly increased flat affect or 5:29 possibly increased flat affect or 5:29 possibly increased flat affect or lowered moon due to low mood due to 5:31 lowered moon due to low mood due to 5:31 lowered moon due to low mood due to lower dopamine production, and muscle 5:34 lower dopamine production, and muscle 5:34 lower dopamine production, and muscle breakdown. So, stay tuned for video two 5:36 breakdown. So, stay tuned for video two 5:36 breakdown. So, stay tuned for video two and we'll talk about what we can do 5:37 and we'll talk about what we can do 5:37 and we'll talk about what we can do about that.
Comments